# ORTIN GLOBAL (NSE: ORTINGLOBE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ORTINGLOBE · Pivot · prices to 21 Oct 2026

ORTIN GLOBAL (NSE: ORTINGLOBE) closed at ₹13.53 on 21 Oct 2026. With a market capitalisation of ₹11 Cr, it ranks 3851st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −42.8% in FY25. Over the past year the share price has risen 16.6%. Its 52-week range is ₹10.66 (28 Oct 2025) to ₹21.30 (9 Jun 2026); the last close is 36.5% below the high. In Q1 FY13, the quarter ended 30 Jun 2012, revenue was ₹13 Cr (−28.5% year on year) and net profit ₹0 Cr (−63.3%), on a consolidated basis. Promoters held 1.23% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹13.53 |
| Market cap | ₹11 Cr |
| ROE | −42.8% (FY25) |
| ROCE | −38.3% (FY25) |
| Debt to equity | 0.13 |
| 52-week high | ₹21.30 (9 Jun 2026) |
| 52-week low | ₹10.66 (28 Oct 2025) |
| 1-year return | +16.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY13 | ₹13 Cr | −28.5% | ₹0 Cr | −63.3% | ₹0.26 |
| Q4 FY12 | ₹17 Cr | — | ₹1 Cr | — | ₹0.84 |
| Q1 FY12 | ₹18 Cr | — | ₹1 Cr | — | ₹0.71 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | −₹1 Cr |
| FY24 | ₹2 Cr | −₹8 Cr |
| FY23 | ₹6 Cr | −₹0 Cr |
| FY22 | ₹8 Cr | −₹0 Cr |
| FY21 | ₹8 Cr | ₹1 Cr |
| FY20 | ₹197 Cr | −₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 1.23%
- Foreign institutions: 1.80%
- Non-institutions: 96.96%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Norris Medicine](https://app.pivotnow.in/stock/NORRIS) | — | ₹14 Cr | — | — |
| [Dolphin Medical](https://app.pivotnow.in/stock/DOLPHMED) | — | ₹12 Cr | — | — |
| [Beryl Drugs](https://app.pivotnow.in/stock/BERLDRG) | — | ₹11 Cr | — | — |
| [Global Longlife](https://app.pivotnow.in/stock/GLHRL) | — | ₹10 Cr | — | — |
| [Looks Health](https://app.pivotnow.in/stock/LOOKS) | — | ₹10 Cr | — | — |
| [Broach Lifecare](https://app.pivotnow.in/stock/BROACH) | — | ₹9 Cr | — | — |

## Questions and answers

### What is the share price of ORTIN GLOBAL today?

ORTIN GLOBAL (NSE: ORTINGLOBE) last closed at ₹13.53 on 21 Oct 2026. Its 52-week high is ₹21.30 and its 52-week low is ₹10.66.

### What is the market cap of ORTIN GLOBAL?

ORTIN GLOBAL's market capitalisation is ₹11 Cr (₹11 Cr) at the 22 Oct 2026 close, ranking 3851st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of ORTIN GLOBAL?

Return on equity was −42.8% in FY25 and return on capital employed was −38.3% in FY25 (standalone figures).

### Is ORTIN GLOBAL a debt-free company?

No. ORTIN GLOBAL's debt-to-equity ratio was 0.13 in FY25, with total debt of ₹0 Cr.

### What were ORTIN GLOBAL's latest quarterly results?

For Q1 FY13 (quarter ended 30 Jun 2012), ORTIN GLOBAL reported revenue of ₹13 Cr, −28.5% year on year, and net profit of ₹0 Cr, −63.3% year on year.

### How has ORTIN GLOBAL stock performed over the last year?

ORTIN GLOBAL's share price has risen 16.6% over the past year, −9.2% over three months and −17.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of ORTIN GLOBAL?

As of 30 Jun 2026: promoters 1.23%, foreign institutions 1.80%, non-institutions 96.96%.

### Who are ORTIN GLOBAL's competitors?

The listed Pharma & Healthcare companies closest to ORTIN GLOBAL by market cap are Norris Medicine, Dolphin Medical, Beryl Drugs, Global Longlife, Looks Health and Broach Lifecare.

### Is ORTIN GLOBAL a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out ORTIN GLOBAL's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ORTINGLOBE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.